On April 23, 2020 Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, reported the appointment of David Michelson, M.D., as Chief Medical Officer (CMO) (Press release, Regenacy Pharmaceuticals, APR 23, 2020, View Source [SID1234556547]). Dr. Michelson has served as Consultant CMO since September 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I’m very pleased to officially welcome David to Regenacy’s team," said Simon Jones, Ph.D., Regenacy’s President and Chief Executive Officer. "For the past 7 months, David’s drug development expertise has been invaluable. He provided tremendous contributions and perspectives on our development strategy for ricolinostat as a consultant, and our team looks forward to continuing to work with him."

"Regenacy is pursuing a novel approach to restoring nerve function that addresses a critical unmet need of patients with peripheral neuropathy," said Dr. Michelson. "It has been a pleasure working alongside Regenacy’s tenured leadership team over the last several months and I look forward to applying my drug development experience to advance ricolinostat into the clinic for DPN."

Dr. Michelson brings over 24 years of industry experience to Regenacy. Prior to joining the company, he served as CMO for Proclara Biosciences where he oversaw multiple Phase 1 studies for a program targeting amyloidosis. Before Proclara, he worked at Merck for 11 years as the Neuroscience Therapeutic Area Head and Vice President for Clinical Development. Dr. Michelson began his career at Eli Lilly and Company, where he held positions of increasing responsibility for early and late stage drug development. Dr. Michelson earned his M.D. from the Albert Einstein College of Medicine in New York, and completed his residency in psychiatry at Yale University, where he also served as a chief resident and faculty member prior to joining the National Institute of Mental Health as a research physician.